Our intent was to investigate whether CTSS inhibition could modulate symptoms of SS-like autoimmune dacryoadenitis using systemic or topical Z-FL as proof-of-principal, not to determine which administration modality was preferable, nor to determine the ideal dosage regimen, both of which would require pharmacokinetics evaluation. Here, CTSS is linked to synovial sarcoma.